Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 389 articles:
HTML format

Single Articles

    August 2022
  1. LIU PH, Wei JC, Wang YH, Yeh MH, et al
    Female breast cancer incidence predisposing risk factors identification using nationwide big data: a matched nested case-control study in Taiwan.
    BMC Cancer. 2022;22:849.
    PubMed     Abstract available

  2. KWON YJ, Seo EB, Jeong AJ, Lee SH, et al
    The acidic tumor microenvironment enhances PD-L1 expression via activation of STAT3 in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2022;22:852.
    PubMed     Abstract available

  3. ZHANG Y, Wu H, Yu Z, Li L, et al
    Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    BMC Cancer. 2022;22:842.
    PubMed     Abstract available

  4. CHO B, Perez M, Jeffe DB, Kreuter MW, et al
    Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer.
    BMC Cancer. 2022;22:837.
    PubMed     Abstract available

    July 2022
  5. LIU N, Yang DW, Wu YX, Xue WQ, et al
    Burden, trends, and risk factors for breast cancer in China from 1990 to 2019 and its predictions until 2034: an up-to-date overview and comparison with those in Japan and South Korea.
    BMC Cancer. 2022;22:826.
    PubMed     Abstract available

  6. RO V, Jones T, Silverman T, McGuinness JE, et al
    Patient, primary care provider, and stakeholder perspectives on mammography screening frequency: lessons learned from a qualitative study.
    BMC Cancer. 2022;22:819.
    PubMed     Abstract available

  7. BRAHIM SM, Zein EE, Bonnet C, Hamed CT, et al
    Screening of BRCA1/2 variants in Mauritanian breast cancer patients.
    BMC Cancer. 2022;22:802.
    PubMed     Abstract available

  8. BHAKKAN-MAMBIR B, Deloumeaux J, Luce D
    Geographical variations of cancer incidence in Guadeloupe, French West Indies.
    BMC Cancer. 2022;22:783.
    PubMed     Abstract available

  9. DOS SANTOS RLB, Pepe VLE, Osorio-de-Castro CGS
    Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019.
    BMC Cancer. 2022;22:769.
    PubMed     Abstract available

  10. FONSECA MM, Alhassan T, Nisha Y, Koszycki D, et al
    Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer- impact on patient anxiety and cancer detection.
    BMC Cancer. 2022;22:774.
    PubMed     Abstract available

  11. TOAMA W, Wiederin J, Shanley R, Jewett P, et al
    Impact of pectoralis muscle loss on cardiac outcome and survival in Cancer patients who received anthracycline based chemotherapy: retrospective study.
    BMC Cancer. 2022;22:763.
    PubMed     Abstract available

  12. JIA L, Li G, Ma N, Zhang A, et al
    Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction.
    BMC Cancer. 2022;22:760.
    PubMed     Abstract available

    June 2022
  13. KHAN MA, Zheng M, Fu J, Tania M, et al
    Thymoquinone upregulates IL17RD in controlling the growth and metastasis of triple negative breast cancer cells in vitro.
    BMC Cancer. 2022;22:707.
    PubMed     Abstract available

  14. PATULEIA SIS, Moelans CB, Koopman J, van Steenhoven JEC, et al
    Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?
    BMC Cancer. 2022;22:705.
    PubMed     Abstract available

  15. BORDE J, Laitman Y, Blumcke B, Niederacher D, et al
    Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
    BMC Cancer. 2022;22:706.
    PubMed     Abstract available

  16. REIS J, Boavida J, Tran HT, Lyngra M, et al
    Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy.
    BMC Cancer. 2022;22:702.
    PubMed     Abstract available

  17. HU K, Wang C, Luo C, Zheng H, et al
    Neuroendocrine pathways and breast cancer progression: a pooled analysis of somatic mutations and gene expression from two large breast cancer cohorts.
    BMC Cancer. 2022;22:680.
    PubMed     Abstract available

  18. WOLF J, Kurz S, Rothe T, Serpa M, et al
    Incidental irradiation of the regional lymph nodes during deep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a dosimetric analysis.
    BMC Cancer. 2022;22:682.
    PubMed     Abstract available

  19. DUZENLI C, Chan EK, Bergman AM, Grahame S, et al
    A novel carbon-fibre adjustable reusable accessory (CARA) for supine breast positioning to reduce toxicity in breast adjuvant radiotherapy: a study protocol for a multicentre phase III randomized controlled trial.
    BMC Cancer. 2022;22:673.
    PubMed     Abstract available

  20. DARBEHESHTI F, Kadkhoda S, Keshavarz-Fathi M, Razi S, et al
    Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    BMC Cancer. 2022;22:668.
    PubMed     Abstract available

  21. SEHOVIC E, Urru S, Chiorino G, Doebler P, et al
    Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection.
    BMC Cancer. 2022;22:634.
    PubMed     Abstract available

  22. YELLAPU NK, Ly T, Sardiu ME, Pei D, et al
    Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
    BMC Cancer. 2022;22:627.
    PubMed     Abstract available

  23. OMARINI C, Piacentini F, Sperduti I, Cerma K, et al
    T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis.
    BMC Cancer. 2022;22:623.
    PubMed     Abstract available

  24. LI XF, Fu WF, Zhang J, Song CG, et al
    An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
    BMC Cancer. 2022;22:619.
    PubMed     Abstract available

  25. WANG Y, Song W, Zhou S, Chang S, et al
    The genomic and transcriptome characteristics of lung adenocarcinoma patients with previous breast cancer.
    BMC Cancer. 2022;22:618.
    PubMed     Abstract available

  26. LI X, An C, Zhang W
    Is it sufficient to evaluate metastatic bone involvement in breast cancer using SPECT/CT? A new approach of SPECT/CT-guided targeted bone marrow biopsy.
    BMC Cancer. 2022;22:614.
    PubMed     Abstract available

    May 2022
  27. AMORNSUPAK K, Thongchot S, Thinyakul C, Box C, et al
    HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2022;22:578.
    PubMed     Abstract available

  28. TSENG CH
    Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
    BMC Cancer. 2022;22:559.
    PubMed     Abstract available

  29. BENTLEY JR, Yu X, Karmarkar AM, Downer B, et al
    Feasibility and thematic analysis of narrative visualization materials with physical activity monitoring among breast cancer survivors.
    BMC Cancer. 2022;22:553.
    PubMed     Abstract available

  30. REN X, Song Y, Zhang Y, Wu H, et al
    Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
    BMC Cancer. 2022;22:548.
    PubMed     Abstract available

  31. KOHLS M, Freisling H, Charvat H, Soerjomataram I, et al
    Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study.
    BMC Cancer. 2022;22:546.
    PubMed     Abstract available

  32. SAYAN M, Eren MF, Kilic SS, Kotek A, et al
    Utilization of radiation therapy and predictors of noncompliance among Syrian refugees in Turkey.
    BMC Cancer. 2022;22:532.
    PubMed     Abstract available

  33. ZENG X, Jiang S, Ruan S, Zhu L, et al
    Cardiovascular risk factors and breast cancer incidence in a large middle-aged cohort study.
    BMC Cancer. 2022;22:534.
    PubMed     Abstract available

  34. ZHOU J, Sun X, Zhang X, Yang H, et al
    miR-107 is involved in the regulation of NEDD9-mediated invasion and metastasis in breast cancer.
    BMC Cancer. 2022;22:533.
    PubMed     Abstract available

  35. NGUYEN VAN LONG F, Lardy-Cleaud A, Carene D, Rossoni C, et al
    Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer.
    BMC Cancer. 2022;22:526.
    PubMed     Abstract available

  36. ESER K, Onder AH, Sezer E, Cil T, et al
    Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
    BMC Cancer. 2022;22:516.
    PubMed     Abstract available

  37. BROWN J, Scardo S, Method M, Schlauch D, et al
    A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
    BMC Cancer. 2022;22:502.
    PubMed     Abstract available

  38. ROUX A, Cholerton R, Sicsic J, Moumjid N, et al
    Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial.
    BMC Cancer. 2022;22:507.
    PubMed     Abstract available

  39. MITAL S, Nguyen HV
    Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening.
    BMC Cancer. 2022;22:501.
    PubMed     Abstract available

  40. MCLAUGHLIN PMJ, Klar M, Zwimpfer TA, Dutilh G, et al
    Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
    BMC Cancer. 2022;22:508.
    PubMed     Abstract available

  41. DELRIEU L, Hamy AS, Coussy F, Kassara A, et al
    Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial.
    BMC Cancer. 2022;22:493.
    PubMed     Abstract available

    April 2022
  42. LI J, Li H, Guan L, Lu Y, et al
    The value of preoperative sentinel lymph node contrast-enhanced ultrasound for breast cancer: a large, multicenter trial.
    BMC Cancer. 2022;22:455.
    PubMed     Abstract available

  43. LEE HJ, Choi CH
    Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
    BMC Cancer. 2022;22:446.
    PubMed     Abstract available

  44. CHEN H, Luo H, Wang J, Li J, et al
    Identification of a pyroptosis-related prognostic signature in breast cancer.
    BMC Cancer. 2022;22:429.
    PubMed     Abstract available

  45. WINTRAECKEN VM, Vulik S, de Wild S, Dirksen C, et al
    A descriptive systematic review of the relationship between personality traits and quality of life of women with non-metastatic breast cancer.
    BMC Cancer. 2022;22:426.
    PubMed     Abstract available

  46. HE Y, Han SB, Liu Y, Zhang JJ, et al
    Role of APOA1 in the resistance to platinum-based chemotherapy in squamous cervical cancer.
    BMC Cancer. 2022;22:411.
    PubMed     Abstract available

  47. LUNARDI M, Al-Habbaa A, Abdelshafy M, Davey MG, et al
    Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review.
    BMC Cancer. 2022;22:396.
    PubMed     Abstract available

  48. GONCALVES R, Mota BS, Sobreira-Lima B, Ricci MD, et al
    The oncological safety of autologous fat grafting: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:391.
    PubMed     Abstract available

  49. XIE Y, Gou Q, Zhang Y, Xie K, et al
    Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China.
    BMC Cancer. 2022;22:385.
    PubMed     Abstract available

  50. HOU C, Xu B, Hao Y, Yang D, et al
    Development and validation of polygenic risk scores for prediction of breast cancer and breast cancer subtypes in Chinese women.
    BMC Cancer. 2022;22:374.
    PubMed     Abstract available

  51. ZERELLA MA, Zaffaroni M, Ronci G, Dicuonzo S, et al
    Single fraction ablative preoperative radiation treatment for early-stage breast cancer: the CRYSTAL study - a phase I/II clinical trial protocol.
    BMC Cancer. 2022;22:358.
    PubMed     Abstract available

  52. REYNOLDS LM, Cavadino A, Chin S, Little Z, et al
    The benefits and acceptability of virtual reality interventions for women with metastatic breast cancer in their homes; a pilot randomised trial.
    BMC Cancer. 2022;22:360.
    PubMed     Abstract available

    March 2022
  53. ZHU GL, Xu C, Yang KB, Tang SQ, et al
    Causal relationship between genetically predicted depression and cancer risk: a two-sample bi-directional mendelian randomization.
    BMC Cancer. 2022;22:353.
    PubMed     Abstract available

  54. SHEWELL LK, Day CJ, Kutasovic JR, Abrahams JL, et al
    N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease.
    BMC Cancer. 2022;22:334.
    PubMed     Abstract available

  55. AMITANI M, Oba T, Kiyosawa N, Morikawa H, et al
    Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer.
    BMC Cancer. 2022;22:327.
    PubMed     Abstract available

  56. MANOUCHEHRI E, Taghipour A, Ebadi A, Homaei Shandiz F, et al
    Understanding breast cancer risk factors: is there any mismatch between laywomen perceptions and expert opinions.
    BMC Cancer. 2022;22:309.
    PubMed     Abstract available

  57. MARTEI YM, Dauda B, Vanderpuye V
    Correction: Breast cancer screening in sub-Saharan Africa: a systematic review and ethical appraisal.
    BMC Cancer. 2022;22:306.

  58. DEN DEKKER BM, Christenhusz A, van Dalen T, Jongen LM, et al
    A multicenter prospective cohort study to evaluate feasibility of radio-frequency identification surgical guidance for nonpalpable breast lesions: design and rationale of the RFID Localizer 1 Trial.
    BMC Cancer. 2022;22:305.
    PubMed     Abstract available

  59. HAN B, Zhen F, Zheng XS, Hu J, et al
    Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer.
    BMC Cancer. 2022;22:297.
    PubMed     Abstract available

  60. SADAQA D, Farraj A, Naseef H, Alsaid H, et al
    Risk of developing depression among breast cancer patients in Palestine.
    BMC Cancer. 2022;22:295.
    PubMed     Abstract available

  61. CHAN KS, Cheung SM, Senn N, Husain E, et al
    Peri-tumoural spatial distribution of lipid composition and tubule formation in breast cancer.
    BMC Cancer. 2022;22:285.
    PubMed     Abstract available

  62. BHARDWAJ A, Embury MD, Ju Z, Wang J, et al
    Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer.
    BMC Cancer. 2022;22:282.
    PubMed     Abstract available

  63. JUNG H, Lu M, Quan ML, Cheung WY, et al
    New method for determining breast cancer recurrence-free survival using routinely collected real-world health data.
    BMC Cancer. 2022;22:281.
    PubMed     Abstract available

  64. DUAN F, Zhong M, Ma Y, Song C, et al
    The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005).
    BMC Cancer. 2022;22:271.
    PubMed     Abstract available

  65. WANG C, Zhou Y, Lin Y, Mao F, et al
    Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
    BMC Cancer. 2022;22:269.
    PubMed     Abstract available

  66. YE F, Bian L, Wen J, Yu P, et al
    Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
    BMC Cancer. 2022;22:261.
    PubMed     Abstract available

  67. YANG PJ, Hou MF, Ou-Yang F, Tsai EM, et al
    Association of early-onset breast cancer with body mass index, menarche, and menopause in Taiwan.
    BMC Cancer. 2022;22:259.
    PubMed     Abstract available

  68. YANG TO, Cairns BJ, Pirie K, Green J, et al
    Body size in early life and the risk of postmenopausal breast cancer.
    BMC Cancer. 2022;22:232.
    PubMed     Abstract available

  69. CHEN YB, Bao HS, Hu TT, He Z, et al
    Comparison of comfort and complications of Implantable Venous Access Port (IVAP) with ultrasound guided Internal Jugular Vein (IJV) and Axillary Vein/Subclavian Vein (AxV/SCV) puncture in breast cancer patients: a randomized controlled study.
    BMC Cancer. 2022;22:248.
    PubMed     Abstract available

  70. HORIMOTO Y, Ishizuka Y, Ueki Y, Higuchi T, et al
    Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients.
    BMC Cancer. 2022;22:242.
    PubMed     Abstract available

  71. LOMAN BR, Russart KLG, Grant CV, Lynch AJ, et al
    Mammary tumors alter the fecal bacteriome and permit enteric bacterial translocation.
    BMC Cancer. 2022;22:245.
    PubMed     Abstract available

  72. TANG R, Deng JP, Zhang L, Zhang WW, et al
    Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy.
    BMC Cancer. 2022;22:234.
    PubMed     Abstract available

  73. ZHANG X, Mu X, Huang O, Wang Z, et al
    ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis.
    BMC Cancer. 2022;22:226.
    PubMed     Abstract available

    February 2022
  74. PARK SY, Lim JW
    Cognitive behavioral therapy for reducing fear of cancer recurrence (FCR) among breast cancer survivors: a systematic review of the literature.
    BMC Cancer. 2022;22:217.
    PubMed     Abstract available

  75. ELBIAD O, Laraqui A, El Boukhrissi F, Mounjid C, et al
    Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    BMC Cancer. 2022;22:208.
    PubMed     Abstract available

  76. MARTEI YM, Dauda B, Vanderpuye V
    Breast cancer screening in sub-Saharan Africa: a systematic review and ethical appraisal.
    BMC Cancer. 2022;22:203.
    PubMed     Abstract available

  77. SARKER R, Islam MS, Moonajilin MS, Rahman M, et al
    Effectiveness of educational intervention on breast cancer knowledge and breast self-examination among female university students in Bangladesh: a pre-post quasi-experimental study.
    BMC Cancer. 2022;22:199.
    PubMed     Abstract available

  78. JUNG JG, Ahn SH, Lee S, Kim EK, et al
    No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial.
    BMC Cancer. 2022;22:189.
    PubMed     Abstract available

  79. CLOUD AS, Vargheese AM, Gunewardena S, Shimak RM, et al
    Loss of REST in breast cancer promotes tumor progression through estrogen sensitization, MMP24 and CEMIP overexpression.
    BMC Cancer. 2022;22:180.
    PubMed     Abstract available

  80. AMBROSIO MR, Magli E, Caliendo G, Sparaco R, et al
    Serotoninergic receptor ligands improve Tamoxifen effectiveness on breast cancer cells.
    BMC Cancer. 2022;22:171.
    PubMed     Abstract available

  81. GOTO W, Kashiwagi S, Kamei Y, Watanabe C, et al
    Relationship between serum lipid levels and the immune microenvironment in breast cancer patients: a retrospective study.
    BMC Cancer. 2022;22:167.
    PubMed     Abstract available

  82. VITALE SR, Ruigrok-Ritstier K, Timmermans AM, Foekens R, et al
    The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
    BMC Cancer. 2022;22:165.
    PubMed     Abstract available

  83. BRAHIMETAJ R, Willekens I, Massart A, Forsyth R, et al
    Improved automated early detection of breast cancer based on high resolution 3D micro-CT microcalcification images.
    BMC Cancer. 2022;22:162.
    PubMed     Abstract available

  84. LIAO Q, Deng D, Xie Q, Gong X, et al
    Clinical characteristics, pregnancy outcomes and ovarian function of pregnancy-associated breast cancer patients: a retrospective age-matched study.
    BMC Cancer. 2022;22:152.
    PubMed     Abstract available

  85. ANDREWS C, Childers TC, Wiseman KD, Lawhon V, et al
    Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.
    BMC Cancer. 2022;22:141.
    PubMed     Abstract available

  86. BU X, Jin C, Fan R, Cheng ASK, et al
    Unmet needs of 1210 Chinese breast cancer survivors and associated factors: a multicentre cross-sectional study.
    BMC Cancer. 2022;22:135.
    PubMed     Abstract available

  87. HEINIG M, Heinze F, Schwarz S, Haug U, et al
    Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery-an analysis of German claims data.
    BMC Cancer. 2022;22:130.
    PubMed     Abstract available

    January 2022
  88. GRAY LA, Hernandez Alava M, Wailoo AJ
    Correction to: Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
    BMC Cancer. 2022;22:112.

  89. VAN EIJK M, Vermunt MAC, van Werkhoven E, Wilthagen EA, et al
    The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    BMC Cancer. 2022;22:104.
    PubMed     Abstract available

  90. ZHONG YM, Tong F, Shen J
    Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:102.
    PubMed     Abstract available

  91. GANESAMOORTHY D, Robertson AJ, Chen W, Hall MB, et al
    Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
    BMC Cancer. 2022;22:85.
    PubMed     Abstract available

  92. RAINEY L, van der Waal D, Donnelly LS, Southworth J, et al
    Women's health behaviour change after receiving breast cancer risk estimates with tailored screening and prevention recommendations.
    BMC Cancer. 2022;22:69.
    PubMed     Abstract available

  93. SALAS M, Mordin M, Castro C, Islam Z, et al
    Health-related quality of life in women with breast cancer: a review of measures.
    BMC Cancer. 2022;22:66.
    PubMed     Abstract available

  94. TAKAMIZAWA S, Shimoi T, Satomi-Tsushita N, Yazaki S, et al
    Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
    BMC Cancer. 2022;22:64.
    PubMed     Abstract available

  95. ZHOU K, Ning F, Wang W, Li X, et al
    The mediator role of resilience between psychological predictors and health-related quality of life in breast cancer survivors: a cross-sectional study.
    BMC Cancer. 2022;22:57.
    PubMed     Abstract available

  96. EKSTROM K, Crescitelli R, Petursson HI, Johansson J, et al
    Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer.
    BMC Cancer. 2022;22:50.
    PubMed     Abstract available

  97. RAUTENBERG T, Hodgkinson B, Zerwes U, Downes M, et al
    Meta-analysis of health state utility values measured by EuroQol 5-dimensions (EQ5D) questionnaire in Chinese women with breast cancer.
    BMC Cancer. 2022;22:52.
    PubMed     Abstract available

  98. VACHENC S, Gobbo J, Moujarrebe SE, Desmoulins I, et al
    OncoSNIPE(R) Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.
    BMC Cancer. 2022;22:41.
    PubMed     Abstract available

  99. WANG S, Jiang H, Zheng C, Gu M, et al
    Secretion of BMP-2 by tumor-associated macrophages (TAM) promotes microcalcifications in breast cancer.
    BMC Cancer. 2022;22:34.
    PubMed     Abstract available

  100. OZAKI Y, Aoyama Y, Masuda J, Inagaki L, et al
    Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
    BMC Cancer. 2022;22:36.
    PubMed     Abstract available

  101. CHITAPANARUX I, Onchan W, Wongmaneerung P, Somwangprasert A, et al
    Integration of breast cancer care in a middle-income country: learning from Suandok Breast Cancer Network (SBCN).
    BMC Cancer. 2022;22:26.
    PubMed     Abstract available

  102. LI L, Ai L, Jia L, Zhang L, et al
    High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.
    BMC Cancer. 2022;22:29.
    PubMed     Abstract available

  103. NAKAMOTO S, Watanabe J, Ohtani S, Morita S, et al
    Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
    BMC Cancer. 2022;22:31.
    PubMed     Abstract available

  104. BOUFERRAA Y, Haibe Y, Chedid A, Jabra E, et al
    The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study.
    BMC Cancer. 2022;22:27.
    PubMed     Abstract available

  105. LEE YJ, Kim Y, Choi BB, Kim JR, et al
    The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer.
    BMC Cancer. 2022;22:12.
    PubMed     Abstract available

  106. HAJJ A, Chamoun R, Salameh P, Khoury R, et al
    Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors.
    BMC Cancer. 2022;22:16.
    PubMed     Abstract available

  107. ESPOSITO MV, Fosso B, Nunziato M, Casaburi G, et al
    Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women.
    BMC Cancer. 2022;22:30.
    PubMed     Abstract available

  108. LAI Z, Brosnan M, Sokol ES, Xie M, et al
    Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    BMC Cancer. 2022;22:13.
    PubMed     Abstract available

    December 2021
  109. BARTMANN C, Fischer LM, Hubner T, Muller-Reiter M, et al
    The effects of the COVID-19 pandemic on psychological stress in breast cancer patients.
    BMC Cancer. 2021;21:1356.
    PubMed     Abstract available

  110. RADES D, Narvaez CA, Dziggel L, Janssen S, et al
    A prospective interventional study investigating sleep disorders prior to and during adjuvant radiotherapy for breast cancer.
    BMC Cancer. 2021;21:1349.
    PubMed     Abstract available

  111. OLSEN M, Fischer K, Bossuyt PM, Goetghebeur E, et al
    Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification.
    BMC Cancer. 2021;21:1351.
    PubMed     Abstract available

  112. KARSONO R, Haryono SJ, Karsono B, Harahap WA, et al
    ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.
    BMC Cancer. 2021;21:1348.
    PubMed     Abstract available

  113. RUFF GL, Murphy KE, Smith ZR, Vertino PM, et al
    Subtype-Independent ANP32E Reduction During Breast Cancer Progression in Accordance with Chromatin Relaxation.
    BMC Cancer. 2021;21:1342.
    PubMed     Abstract available

  114. PARK HL, Chang J, Haridass V, Wang SS, et al
    Mammography screening and mortality by risk status in the California teachers study.
    BMC Cancer. 2021;21:1341.
    PubMed     Abstract available

  115. ZHANG MK, Wang B, Li SY, Liu G, et al
    TGF-beta1 and its signal molecules: are they correlated with the elasticity characteristics of breast lesions?
    BMC Cancer. 2021;21:1336.
    PubMed     Abstract available

  116. LIN S, Mo H, Li Y, Guan X, et al
    Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.
    BMC Cancer. 2021;21:1330.
    PubMed     Abstract available

  117. XU D, Zhang Y, Jin F
    The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining.
    BMC Cancer. 2021;21:1321.
    PubMed     Abstract available

  118. LI F, Sun H, Li Y, Bai X, et al
    High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.
    BMC Cancer. 2021;21:1305.
    PubMed     Abstract available

  119. ZHANG J, Jiang H, Zhang J, Bao G, et al
    Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.
    BMC Cancer. 2021;21:1301.
    PubMed     Abstract available

  120. GIACOMELLI C, Jung J, Wachter A, Ibing S, et al
    Coordinated regulation of WNT/beta-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
    BMC Cancer. 2021;21:1296.
    PubMed     Abstract available

  121. KEPESIDIS KV, Bozic-Iven M, Huber M, Abdel-Aziz N, et al
    Breast-cancer detection using blood-based infrared molecular fingerprints.
    BMC Cancer. 2021;21:1287.
    PubMed     Abstract available

  122. JIANG H, Meng L, Zhang H, Dai X, et al
    Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions.
    BMC Cancer. 2021;21:1284.
    PubMed     Abstract available

    November 2021
  123. MAZZONI AS, Brooke HL, Berntsen S, Nordin K, et al
    Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of the Phys-Can RCT.
    BMC Cancer. 2021;21:1272.
    PubMed     Abstract available

  124. MASUDA N, Tamura K, Yasojima H, Shimomura A, et al
    Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
    BMC Cancer. 2021;21:1269.
    PubMed     Abstract available

  125. XIN Y, Shen G, Zheng Y, Guan Y, et al
    Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:1261.
    PubMed     Abstract available

  126. KLEIN I, Kalichman L, Chen N, Susmallian S, et al
    A comprehensive approach to risk factors for upper arm morbidities following breast cancer treatment: a prospective study.
    BMC Cancer. 2021;21:1251.
    PubMed     Abstract available

  127. SHI Y, Liu C
    Circular RNA hsa_circ_0043278 inhibits breast cancer progression via the miR-455-3p/EI24 signalling pathway.
    BMC Cancer. 2021;21:1249.
    PubMed     Abstract available

  128. GRAY LA, Hernandez Alava M, Wailoo AJ
    Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
    BMC Cancer. 2021;21:1237.
    PubMed     Abstract available

  129. ZHENG G, Sundquist J, Sundquist K, Ji J, et al
    Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study.
    BMC Cancer. 2021;21:1210.
    PubMed     Abstract available

  130. CHOI SH, Yoon HS, Yoo SA, Yun SH, et al
    Correction to: Co-relation with novel phosphorylation sites of IkappaBalpha and necroptosis in breast cancer cells.
    BMC Cancer. 2021;21:1198.

  131. MIGEOTTE A, Dufour V, van Maanen A, Berliere M, et al
    Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
    BMC Cancer. 2021;21:1204.
    PubMed     Abstract available

  132. WANG Z, Hu S, Li X, Liu Z, et al
    MiR-16-5p suppresses breast cancer proliferation by targeting ANLN.
    BMC Cancer. 2021;21:1188.
    PubMed     Abstract available

  133. ZHAO XR, Fang H, Tang Y, Hu ZH, et al
    POstmastectomy radioThErapy in Node-posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a study protocol for a multicenter prospective phase III randomized controlled trial.
    BMC Cancer. 2021;21:1185.
    PubMed     Abstract available

  134. VAN PARIJS H, Vinh-Hung V, Fontaine C, Storme G, et al
    Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer.
    BMC Cancer. 2021;21:1177.
    PubMed     Abstract available

  135. WIJERATNE DT, Gunasekera S, Booth CM, Promod H, et al
    Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry.
    BMC Cancer. 2021;21:1175.
    PubMed     Abstract available

  136. XIE Y, Gong C, Zhang J, Wang L, et al
    Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
    BMC Cancer. 2021;21:1174.
    PubMed     Abstract available

    October 2021
  137. TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
    Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
    BMC Cancer. 2021;21:1168.
    PubMed     Abstract available

  138. TANG W, Xu F, Zhao M, Zhang S, et al
    Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
    BMC Cancer. 2021;21:1160.
    PubMed     Abstract available

  139. CREEDEN JF, Nanavaty NS, Einloth KR, Gillman CE, et al
    Homologous recombination proficiency in ovarian and breast cancer patients.
    BMC Cancer. 2021;21:1154.
    PubMed     Abstract available

  140. SAJJADI E, Venetis K, Piciotti R, Gambini D, et al
    Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
    BMC Cancer. 2021;21:1152.
    PubMed     Abstract available

  141. KIM K, Kim IJ, Pak K, Kang T, et al
    Prognostic value of metabolic activity of the psoas muscle evaluated by preoperative (18)F-FDG PET-CT in breast cancer: a retrospective cross-sectional study.
    BMC Cancer. 2021;21:1151.
    PubMed     Abstract available

  142. AL RABADI LS, Cook MM, Kaempf AJ, Saraceni MM, et al
    Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    BMC Cancer. 2021;21:1150.
    PubMed     Abstract available

  143. SHIMOI T, Hashimoto J, Sudo K, Shimomura A, et al
    Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
    BMC Cancer. 2021;21:1131.
    PubMed     Abstract available

  144. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy.
    BMC Cancer. 2021;21:1129.
    PubMed     Abstract available

  145. BERTOZZI S, Londero AP, Viola L, Orsaria M, et al
    TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study.
    BMC Cancer. 2021;21:1118.
    PubMed     Abstract available

  146. MERINO T, Pinto MP, Orellana MP, Martinez G, et al
    Multimodal assessment of acute cardiac toxicity induced by thoracic radiotherapy in cancer patients. Study protocol.
    BMC Cancer. 2021;21:1114.
    PubMed     Abstract available

  147. AHSBERG K, Gardfjell A, Nimeus E, Ryden L, et al
    The PROCEM study protocol: Added value of preoperative contrast-enhanced mammography in staging of malignant breast lesions - a prospective randomized multicenter study.
    BMC Cancer. 2021;21:1115.
    PubMed     Abstract available

  148. HE Y, Tao Q, Zhou F, Si Y, et al
    The relationship between dairy products intake and breast cancer incidence: a meta-analysis of observational studies.
    BMC Cancer. 2021;21:1109.
    PubMed     Abstract available

  149. KIRKHAM AA, King K, Joy AA, Pelletier AB, et al
    Rationale and design of the Diet Restriction and Exercise-induced Adaptations in Metastatic breast cancer (DREAM) study: a 2-arm, parallel-group, phase II, randomized control trial of a short-term, calorie-restricted, and ketogenic diet plus exercise
    BMC Cancer. 2021;21:1093.
    PubMed     Abstract available

  150. TSUKAMOTO F, Arihiro K, Takahashi M, Ito KI, et al
    Multicenter retrospective study on the use of Curebest 95GC Breast for estrogen receptor-positive and node-negative early breast cancer.
    BMC Cancer. 2021;21:1077.
    PubMed     Abstract available

    September 2021
  151. LEE J, Jung JH, Kim WW, Kang B, et al
    Short-term serial assessment of electronic patient-reported outcome for depression and anxiety in breast Cancer.
    BMC Cancer. 2021;21:1065.
    PubMed     Abstract available

  152. LIN Y, Zhou X, Peng W, Wu J, et al
    Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.
    BMC Cancer. 2021;21:1062.
    PubMed     Abstract available

  153. ABEBE E, Tollesa T, Assefa M, Tilahun Z, et al
    Cognitive functioning and its associated factors among breast cancer patients on chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa Ethiopia: an institution-based comparative cross-sectional study.
    BMC Cancer. 2021;21:1052.
    PubMed     Abstract available

  154. AKINYEMIJU T, Jones K, Gupta A, Oyekunle T, et al
    Association of body composition with odds of breast cancer by molecular subtype: analysis of the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Nigerian Women (MEND) study.
    BMC Cancer. 2021;21:1051.
    PubMed     Abstract available

  155. RODRIGUEZ-ACEVEDO AJ, Chan RJ, Olsen CM, Pandeya N, et al
    Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
    BMC Cancer. 2021;21:1055.
    PubMed     Abstract available

  156. RAGALA MEA, El Hilaly J, Amaadour L, Omari M, et al
    Validation of Mini-Mental Adjustment to Cancer scale in a Moroccan sample of breast cancer women.
    BMC Cancer. 2021;21:1042.
    PubMed     Abstract available

  157. JAKOBSEN M, Kolodziejczyk C, Jensen MS, Poulsen PB, et al
    Cardiovascular disease in women with breast cancer - a nationwide cohort study.
    BMC Cancer. 2021;21:1040.
    PubMed     Abstract available

  158. STURKEN C, Mobus V, Milde-Langosch K, Schmatloch S, et al
    Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
    BMC Cancer. 2021;21:1024.

  159. ZHANG X, Pang X, Zhang Z, Liu Q, et al
    Co-expression and prognosis analyses of GLUT1-4 and RB1 in breast cancer.
    BMC Cancer. 2021;21:1026.
    PubMed     Abstract available

  160. LIU J, Yin J, Liu Y, Xu Z, et al
    Characteristics of 1270 Chinese sibling pairs with cancer.
    BMC Cancer. 2021;21:1027.
    PubMed     Abstract available

  161. TAY MRJ, Wong CJ, Aw HZ
    Prevalence and associations of axillary web syndrome in Asian women after breast cancer surgery undergoing a community-based cancer rehabilitation program.
    BMC Cancer. 2021;21:1019.
    PubMed     Abstract available

  162. DIMITROVA D, Naghavi B, Richter R, Nasser S, et al
    Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
    BMC Cancer. 2021;21:1018.
    PubMed     Abstract available

  163. NIU T, Wu Z, Xiao W
    Uev1A promotes breast cancer cell migration by up-regulating CT45A expression via the AKT pathway.
    BMC Cancer. 2021;21:1012.
    PubMed     Abstract available

  164. FUKUI J, White K, Frankland TB, Oshiro C, et al
    Weight changes according to treatment in a diverse cohort of breast cancer patients.
    BMC Cancer. 2021;21:1005.
    PubMed     Abstract available

  165. MARCELINO AC, Gozzi B, Cardoso-Filho C, Machado H, et al
    Race disparities in mortality by breast cancer from 2000 to 2017 in Sao Paulo, Brazil: a population-based retrospective study.
    BMC Cancer. 2021;21:998.
    PubMed     Abstract available

  166. AMAYA C, Luo S, Baigorri J, Baucells R, et al
    Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
    BMC Cancer. 2021;21:981.
    PubMed     Abstract available

    August 2021
  167. SZWIEC M, Tomiczek-Szwiec J, Kluzniak W, Wokolorczyk D, et al
    Genetic predisposition to male breast cancer in Poland.
    BMC Cancer. 2021;21:975.
    PubMed     Abstract available

  168. HACKSHAW MD, Danysh HE, Henderson M, Wang E, et al
    Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
    BMC Cancer. 2021;21:967.
    PubMed     Abstract available

  169. LI Y, Ma L
    Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer.
    BMC Cancer. 2021;21:965.
    PubMed     Abstract available

  170. DAI YH, Wang YF, Shen PC, Lo CH, et al
    Gene-associated methylation status of ST14 as a predictor of survival and hormone receptor positivity in breast Cancer.
    BMC Cancer. 2021;21:945.
    PubMed     Abstract available

  171. MOON SY, Lee H, Kim S, Hong JH, et al
    Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    BMC Cancer. 2021;21:931.
    PubMed     Abstract available

  172. STURKEN C, Mobus V, Milde-Langosch K, Schmatloch S, et al
    TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
    BMC Cancer. 2021;21:920.
    PubMed     Abstract available

  173. ZHANG Y, Zhang D, Meng Q, Liu Z, et al
    Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level.
    BMC Cancer. 2021;21:918.
    PubMed     Abstract available

  174. SU TP, Huang JS, Chang PH, Lui KW, et al
    Prospective comparison of early interim (18)F-FDG-PET with (18)F-FLT-PET for predicting treatment response and survival in metastatic breast cancer.
    BMC Cancer. 2021;21:908.
    PubMed     Abstract available

  175. DE CALUWE A, Buisseret L, Poortmans P, Van Gestel D, et al
    Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.
    BMC Cancer. 2021;21:899.
    PubMed     Abstract available

  176. CHEBET JJ, Ehiri JE, McClelland DJ, Taren D, et al
    Effect of d-limonene and its derivatives on breast cancer in human trials: a scoping review and narrative synthesis.
    BMC Cancer. 2021;21:902.
    PubMed     Abstract available

  177. TAVARES MC, Sampaio CD, Lima GE, Andrade VP, et al
    A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
    BMC Cancer. 2021;21:901.
    PubMed     Abstract available

  178. ALGEO N, Bennett K, Connolly D
    Rehabilitation interventions to support return to work for women with breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:895.
    PubMed     Abstract available

  179. CHAN RJ, Cooper B, Gordon L, Hart N, et al
    Distinct employment interference profiles in patients with breast cancer prior to and for 12 months following surgery.
    BMC Cancer. 2021;21:883.
    PubMed     Abstract available

  180. WANG Y, Men X, Gu Y, Wang H, et al
    Haplotype analysis on correlation between transcription factor 7-like 2 gene polymorphism and breast cancer risk.
    BMC Cancer. 2021;21:885.
    PubMed     Abstract available

    July 2021
  181. WANG G, Zhang S, Wang M, Liu L, et al
    Prognostic significance of occult lymph node metastases in breast cancer: a meta-analysis.
    BMC Cancer. 2021;21:875.
    PubMed     Abstract available

  182. HAJJ A, Hachem R, Khoury R, Hallit S, et al
    Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study.
    BMC Cancer. 2021;21:872.
    PubMed     Abstract available

  183. WU W, Chen J, Deng H, Jin L, et al
    Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.
    BMC Cancer. 2021;21:862.
    PubMed     Abstract available

  184. TURKISTANI S, Sugita BM, Fadda P, Marchi R, et al
    A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
    BMC Cancer. 2021;21:861.
    PubMed     Abstract available

  185. JANG MK, Han J, Kim SH, Ko YH, et al
    Comparison of fatigue and fatigability correlates in Korean breast cancer survivors and differences in associations with anxiety, depression, sleep disturbance, and endocrine symptoms: a randomized controlled trial.
    BMC Cancer. 2021;21:855.
    PubMed     Abstract available

  186. LEI YY, Ho SC, Kwok C, Cheng A, et al
    Weight and waist-to-hip ratio change pattern during the first five years of survival: data from a longitudinal observational Chinese breast cancer cohort.
    BMC Cancer. 2021;21:839.
    PubMed     Abstract available

  187. JIANG J, Chen J, Li W, Li Y, et al
    Inter-observer variations of the tumor bed delineation for patients after breast conserving surgery in preoperative magnetic resonance and computed tomography scan fusion.
    BMC Cancer. 2021;21:838.
    PubMed     Abstract available

  188. LU H, Zha S, Zhang W, Wang Q, et al
    A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.
    BMC Cancer. 2021;21:830.
    PubMed     Abstract available

  189. VIALA M, Firmin N, Touraine C, Pouderoux S, et al
    Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer.
    BMC Cancer. 2021;21:815.
    PubMed     Abstract available

  190. LI S, Wu J, Huang O, He J, et al
    Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients.
    BMC Cancer. 2021;21:807.
    PubMed     Abstract available

  191. SONG D, Hu Y, Diao B, Miao R, et al
    Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer.
    BMC Cancer. 2021;21:798.
    PubMed     Abstract available

  192. NAKAYAMA T, Yoshinami T, Yasojima H, Kittaka N, et al
    Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
    BMC Cancer. 2021;21:795.
    PubMed     Abstract available

  193. LAMBERT P, Pitz M, Singh H, Decker K, et al
    Evaluation of algorithms using administrative health and structured electronic medical record data to determine breast and colorectal cancer recurrence in a Canadian province : Using algorithms to determine breast and colorectal cancer recurrence.
    BMC Cancer. 2021;21:763.
    PubMed     Abstract available

    June 2021
  194. JIAO X, Wang B, Feng C, Song S, et al
    Formin-like protein 2 promotes cell proliferation by a p27-related mechanism in human breast cancer cells.
    BMC Cancer. 2021;21:760.
    PubMed     Abstract available

  195. ZHAO Q, Hughes R, Neupane B, Mickle K, et al
    Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer.
    BMC Cancer. 2021;21:758.
    PubMed     Abstract available

  196. GAO J, Wang S, Zhang Z, Li J, et al
    Long non-coding RNA BRE-AS1 inhibits the proliferation, migration, and invasion of cancer cells in triple-negative breast cancer and predicts patients' survival by downregulating miR-21.
    BMC Cancer. 2021;21:745.
    PubMed     Abstract available

  197. HE C, Zhu WX, Tang Y, Bai Y, et al
    Knowledge of a cancer diagnosis is a protective factor for the survival of patients with breast cancer: a retrospective cohort study.
    BMC Cancer. 2021;21:739.
    PubMed     Abstract available

  198. YOO TK, Park SH, Do Han K, Chae BJ, et al
    Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ.
    BMC Cancer. 2021;21:735.
    PubMed     Abstract available

  199. WANG K, Jin X, Wang W, Yu X, et al
    The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis.
    BMC Cancer. 2021;21:728.
    PubMed     Abstract available

  200. HALLER H, Voiss P, Cramer H, Paul A, et al
    The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women's response to integrative breast cancer treatment.
    BMC Cancer. 2021;21:724.
    PubMed     Abstract available

  201. GUO L, Xie G, Wang R, Yang L, et al
    Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?
    BMC Cancer. 2021;21:717.
    PubMed     Abstract available

  202. BAKOS B, Kiss A, Arvai K, Szili B, et al
    Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden.
    BMC Cancer. 2021;21:706.
    PubMed     Abstract available

  203. YU J, Lin C, Huang J, Hong J, et al
    Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer.
    BMC Cancer. 2021;21:707.
    PubMed     Abstract available

  204. DONG J, Sun Q, Pan Y, Lu N, et al
    Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.
    BMC Cancer. 2021;21:700.
    PubMed     Abstract available

  205. SUN M, Tang C, Liu J, Jiang W, et al
    Comprehensive analysis of suppressor of cytokine signaling proteins in human breast Cancer.
    BMC Cancer. 2021;21:696.
    PubMed     Abstract available

  206. BREIDENBACH C, Wesselmann S, Sibert NT, Ortmann O, et al
    Use of social service counseling by cancer patients: an analysis of quality assurance data of 6339 breast cancer patients from 13 certified centers in Germany treated between 2015 and 2017.
    BMC Cancer. 2021;21:671.
    PubMed     Abstract available

  207. DHAKA B, Sabarinathan R
    Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
    BMC Cancer. 2021;21:669.
    PubMed     Abstract available

  208. KOTNIK U, Peterlin B, Lovrecic L
    Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
    BMC Cancer. 2021;21:665.
    PubMed     Abstract available

  209. BORRERO-GARCIA LD, Del Mar Maldonado M, Medina-Velazquez J, Troche-Torres AL, et al
    Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
    BMC Cancer. 2021;21:652.
    PubMed     Abstract available

    May 2021
  210. WOO J, Oh SJ, Song JY, Chae BJ, et al
    Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study.
    BMC Cancer. 2021;21:647.
    PubMed     Abstract available

  211. HUANG S, Hu P, Lakowski TM
    Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
    BMC Cancer. 2021;21:648.
    PubMed     Abstract available

  212. WANG D, Wei G, Ma J, Cheng S, et al
    Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients.
    BMC Cancer. 2021;21:645.
    PubMed     Abstract available

  213. FOSTER M, Niedzwiedz CL
    Associations between multimorbidity and depression among breast cancer survivors within the UK Biobank cohort: a cross-sectional study.
    BMC Cancer. 2021;21:650.
    PubMed     Abstract available

  214. LIU Y, Teng L, Fu S, Wang G, et al
    Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    BMC Cancer. 2021;21:644.
    PubMed     Abstract available

  215. MCWILLIAMS L, Woof VG, Donnelly LS, Howell A, et al
    Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?
    BMC Cancer. 2021;21:637.
    PubMed     Abstract available

  216. ZHENG L, Zheng F, Xing Z, Zhang Y, et al
    Breast lesions excised via vacuum-assisted system: could we get any clues for B3 lesions before excision biopsy?
    BMC Cancer. 2021;21:633.
    PubMed     Abstract available

  217. CHOI SH, Yoon HS, Yoo SA, Yun SH, et al
    Co-relation with novel phosphorylation sites of IkappaBalpha and necroptosis in breast cancer cells.
    BMC Cancer. 2021;21:596.
    PubMed     Abstract available

  218. ANWAR SL, Cahyono R, Prabowo D, Avanti WS, et al
    Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.
    BMC Cancer. 2021;21:590.
    PubMed     Abstract available

  219. HAN P, Zhu J, Feng G, Wang Z, et al
    Characterization of alternative splicing events and prognostic signatures in breast cancer.
    BMC Cancer. 2021;21:587.
    PubMed     Abstract available

  220. ZOGRAFOS E, Korakiti AM, Andrikopoulou A, Rellias I, et al
    Germline mutations in a clinic-based series of pregnancy associated breast cancer patients.
    BMC Cancer. 2021;21:572.
    PubMed     Abstract available

  221. ZHANG Y, Asad S, Weber Z, Tallman D, et al
    Genomic features of rapid versus late relapse in triple negative breast cancer.
    BMC Cancer. 2021;21:568.
    PubMed     Abstract available

  222. CHAN CWH, Law BMH, Ng MSN, Wong CCY, et al
    Association of single nucleotide polymorphisms of cytochrome P450 enzymes with experience of vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients: a systematic review.
    BMC Cancer. 2021;21:570.
    PubMed     Abstract available

  223. ZHANG M, Wang B, Liu N, Wang H, et al
    Nomogram for predicting preoperative regional lymph nodes metastasis in patients with metaplastic breast cancer: a SEER population-based study.
    BMC Cancer. 2021;21:565.
    PubMed     Abstract available

  224. NITTALA MR, Mundra EK, Packianathan S, Mehta D, et al
    The Will Rogers phenomenon, breast cancer and race.
    BMC Cancer. 2021;21:554.
    PubMed     Abstract available

  225. MILLS MN, Naz A, Thawani C, Walker C, et al
    Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
    BMC Cancer. 2021;21:552.
    PubMed     Abstract available

  226. KOTANI H, Terada M, Mori M, Horisawa N, et al
    Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.
    BMC Cancer. 2021;21:548.
    PubMed     Abstract available

  227. WANG Y, Wang Y, Chen R, Tang Z, et al
    Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: a retrospective study of 1004 Chinese breast cancer patients.
    BMC Cancer. 2021;21:542.
    PubMed     Abstract available

  228. YANG S, Bian J, George TJ, Daily K, et al
    The association between cognitive impairment and breast and colorectal cancer screening utilization.
    BMC Cancer. 2021;21:539.
    PubMed     Abstract available

  229. ZHOU X, Zheng Z, Li Y, Zhao W, et al
    The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study.
    BMC Cancer. 2021;21:536.
    PubMed     Abstract available

  230. SOOD R, Masalu N, Connolly RM, Chao CA, et al
    Invasive breast Cancer treatment in Tanzania: landscape assessment to prepare for implementation of standardized treatment guidelines.
    BMC Cancer. 2021;21:527.
    PubMed     Abstract available

  231. WANG B, Wang H, Zhao A, Zhang M, et al
    Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits.
    BMC Cancer. 2021;21:523.
    PubMed     Abstract available

  232. YANG JR, Kuo WL, Yu CC, Chen SC, et al
    Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study.
    BMC Cancer. 2021;21:522.
    PubMed     Abstract available

  233. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed     Abstract available

  234. WOODS LM, Rachet B, Morris M, Bhaskaran K, et al
    Are socio-economic inequalities in breast cancer survival explained by peri-diagnostic factors?
    BMC Cancer. 2021;21:485.
    PubMed     Abstract available

  235. EOM KY, van Londen GJ, Li J, Dahman B, et al
    Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform.
    BMC Cancer. 2021;21:487.
    PubMed     Abstract available

    April 2021
  236. YUAN Y, Xiao WW, Xie WH, Li RZ, et al
    Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer.
    BMC Cancer. 2021;21:479.
    PubMed     Abstract available

  237. YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
    New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    BMC Cancer. 2021;21:476.
    PubMed     Abstract available

  238. MAJED SO, Mustafa SA
    MACE-Seq-based coding RNA and TrueQuant-based small RNA profile in breast cancer: tumor-suppressive miRNA-1275 identified as a novel marker.
    BMC Cancer. 2021;21:473.
    PubMed     Abstract available

  239. YU Y, Wang Z, Wei Z, Yu B, et al
    Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1-2 positive sentinel lymph node macro-metastases: a retrospective analysis of two independent cohorts.
    BMC Cancer. 2021;21:466.
    PubMed     Abstract available

  240. ANDRIKOPOULOU A, Apostolidou K, Chatzinikolaou S, Bletsa G, et al
    Trastuzumab administration during pregnancy: un update.
    BMC Cancer. 2021;21:463.
    PubMed     Abstract available

  241. LIU H, Shi W, Jin Z, Zhuo R, et al
    Global, regional, and national mortality trends of female breast cancer by risk factor, 1990-2017.
    BMC Cancer. 2021;21:459.
    PubMed     Abstract available

  242. NAJAFI S, Ansari M, Kaveh V, Haghighat S, et al
    Comparing the efficacy and side-effects of PDLASTA(R) (Pegfilgrastim) with PDGRASTIM(R) (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial.
    BMC Cancer. 2021;21:454.
    PubMed     Abstract available

  243. HOUSE BJ, Kwon MJ, Schaefer JM, Barth CW, et al
    Clinically relevant dual probe difference specimen imaging (DDSI) protocol for freshly resected breast cancer specimen staining.
    BMC Cancer. 2021;21:440.
    PubMed     Abstract available

  244. JANEVA S, Parris TZ, Nasic S, De Lara S, et al
    Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
    BMC Cancer. 2021;21:439.
    PubMed     Abstract available

  245. YAMAGUCHI J, Moriuchi H, Ueda T, Kawashita Y, et al
    Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
    BMC Cancer. 2021;21:434.
    PubMed     Abstract available

  246. TAN Z, Zou Y, Zhu M, Luo Z, et al
    Carnitine palmitoyl transferase 1A is a novel diagnostic and predictive biomarker for breast cancer.
    BMC Cancer. 2021;21:409.
    PubMed     Abstract available

  247. LV R, Yang G, Huang Y, Wang Y, et al
    Dosimetric effects of supine immobilization devices on the skin in intensity-modulated radiation therapy for breast cancer: a retrospective study.
    BMC Cancer. 2021;21:384.
    PubMed     Abstract available

  248. LIANG G, Ma W, Zhao Y, Liu E, et al
    Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
    BMC Cancer. 2021;21:362.
    PubMed     Abstract available

  249. LIU Z, Liu J, Liu R, Xue M, et al
    Downregulated ZNF132 predicts unfavorable outcomes in breast Cancer via Hypermethylation modification.
    BMC Cancer. 2021;21:367.
    PubMed     Abstract available

  250. REECE JC, Neal EFG, Nguyen P, McIntosh JG, et al
    Delayed or failure to follow-up abnormal breast cancer screening mammograms in primary care: a systematic review.
    BMC Cancer. 2021;21:373.
    PubMed     Abstract available

  251. AREFAN D, Hausler RM, Sumkin JH, Sun M, et al
    Predicting cell invasion in breast tumor microenvironment from radiological imaging phenotypes.
    BMC Cancer. 2021;21:370.
    PubMed     Abstract available

  252. CABIOGLU N, Onder S, Oner G, Karatay H, et al
    TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.
    BMC Cancer. 2021;21:357.
    PubMed     Abstract available

    March 2021
  253. COLOMBIE M, Jezequel P, Rubeaux M, Frenel JS, et al
    The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients.
    BMC Cancer. 2021;21:333.
    PubMed     Abstract available

  254. CHEN S, Han Y, Ouyang Q, Lu J, et al
    Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy.
    BMC Cancer. 2021;21:341.
    PubMed     Abstract available

  255. CHU CN, Hu KC, Wu RS, Bau DT, et al
    Radiation-irritated skin and hyperpigmentation may impact the quality of life of breast cancer patients after whole breast radiotherapy.
    BMC Cancer. 2021;21:330.
    PubMed     Abstract available

  256. CHEN L, Dong Y, Pan Y, Zhang Y, et al
    Identification and development of an independent immune-related genes prognostic model for breast cancer.
    BMC Cancer. 2021;21:329.
    PubMed     Abstract available

  257. FALCICCHIO C, Di Lallo D, Fabi A, Bonucci A, et al
    Use of rehabilitation pathways in women with breast cancer in the first 12 months of the disease: a retrospective study.
    BMC Cancer. 2021;21:311.
    PubMed     Abstract available

  258. ALOMRAN R, White M, Bruce M, Bressel M, et al
    Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).
    BMC Cancer. 2021;21:303.
    PubMed     Abstract available

  259. SANDVEI MS, Opdahl S, Valla M, Lagiou P, et al
    The association of women's birth size with risk of molecular breast cancer subtypes: a cohort study.
    BMC Cancer. 2021;21:299.
    PubMed     Abstract available

  260. JAYASINGHE R, Fernando A, Jayarajah U, Seneviratne S, et al
    Post treatment quality of life among Sri Lankan women with breast cancer.
    BMC Cancer. 2021;21:305.
    PubMed     Abstract available

  261. YUAN Q, Hou J, He Y, Liao Y, et al
    Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level.
    BMC Cancer. 2021;21:293.
    PubMed     Abstract available

  262. KURODA H, Jamiyan T, Yamaguchi R, Kakumoto A, et al
    Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
    BMC Cancer. 2021;21:286.
    PubMed     Abstract available

  263. LIN B, Liu C, Shi E, Jin Q, et al
    MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4.
    BMC Cancer. 2021;21:275.
    PubMed     Abstract available

  264. ZEPPELLINI A, Galimberti S, Leone BE, Pacifico C, et al
    Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
    BMC Cancer. 2021;21:260.
    PubMed     Abstract available

  265. SATO A, Matsubayashi K, Morishima T, Nakata K, et al
    Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
    BMC Cancer. 2021;21:264.
    PubMed     Abstract available

  266. LI C, Tao C, Bai T, Li Z, et al
    Beam complexity and monitor unit efficiency comparison in two different volumetric modulated arc therapy delivery systems using automated planning.
    BMC Cancer. 2021;21:261.
    PubMed     Abstract available

  267. JI L, Cheng L, Zhu X, Gao Y, et al
    Risk and prognostic factors of breast cancer with liver metastases.
    BMC Cancer. 2021;21:238.
    PubMed     Abstract available

  268. YOSHIKAWA K, Ishida M, Yanai H, Tsuta K, et al
    Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
    BMC Cancer. 2021;21:239.
    PubMed     Abstract available

  269. HERRMANN C, Morant R, Walser E, Mousavi M, et al
    Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects.
    BMC Cancer. 2021;21:229.
    PubMed     Abstract available

  270. WIND A, Hartman ED, Van Eekeren RRJP, Wijn RPWF, et al
    Validating a generic cancer consumer quality index in eight European countries, patient reported experiences and the influence of cultural differences.
    BMC Cancer. 2021;21:231.
    PubMed     Abstract available

  271. LIU X, Zheng D, Wu Y, Luo C, et al
    Treatment patterns and outcomes in older women with early breast cancer: a population-based cohort study in China.
    BMC Cancer. 2021;21:226.
    PubMed     Abstract available

  272. HUANG Z, Zhou X, Tong Y, Zhu L, et al
    Surgery for primary tumor benefits survival for breast cancer patients with bone metastases: a large cohort retrospective study.
    BMC Cancer. 2021;21:222.
    PubMed     Abstract available

  273. MILLS MN, Walker C, Thawani C, Naz A, et al
    Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
    BMC Cancer. 2021;21:223.
    PubMed     Abstract available

  274. TOPNO R, Singh I, Kumar M, Agarwal P, et al
    Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer.
    BMC Cancer. 2021;21:220.
    PubMed     Abstract available

  275. WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
    BMC Cancer. 2021;21:215.
    PubMed     Abstract available

  276. ZHANG SL, Song J, Wang YR, Guo YJ, et al
    Short-term outcomes and safety of radiotherapy for immediate breast reconstruction with autologous flap transfer following breast-conserving surgery.
    BMC Cancer. 2021;21:214.
    PubMed     Abstract available

  277. OLOW AK, Veer LV', Wolf DM
    Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments.
    BMC Cancer. 2021;21:212.
    PubMed     Abstract available

    February 2021
  278. ZHAO F, Hao Z, Zhong Y, Xu Y, et al
    Discovery of breast cancer risk genes and establishment of a prediction model based on estrogen metabolism regulation.
    BMC Cancer. 2021;21:194.
    PubMed     Abstract available

  279. YU L, Shi Q, Jin Y, Liu Z, et al
    Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study.
    BMC Cancer. 2021;21:195.
    PubMed     Abstract available

  280. HUANG CC, Tsai YF, Liu CY, Chao TC, et al
    Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
    BMC Cancer. 2021;21:199.
    PubMed     Abstract available

  281. MATSON DR, Denu RA, Zasadil LM, Burkard ME, et al
    High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability.
    BMC Cancer. 2021;21:186.
    PubMed     Abstract available

  282. TSUJI K, Matsuoka YJ, Ochi E
    High-intensity interval training in breast cancer survivors: a systematic review.
    BMC Cancer. 2021;21:184.
    PubMed     Abstract available

  283. BERGER K, Rhost S, Rafnsdottir S, Hughes E, et al
    Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer.
    BMC Cancer. 2021;21:185.
    PubMed     Abstract available

  284. LEE J, Park HY, Kim WW, Lee JJ, et al
    Natural course of fat necrosis after breast reconstruction: a 10-year follow-up study.
    BMC Cancer. 2021;21:166.
    PubMed     Abstract available

  285. LIU J, Zheng X, Han Z, Lin S, et al
    Clinical characteristics and overall survival prognostic nomogram for invasive cribriform carcinoma of breast: a SEER population-based analysis.
    BMC Cancer. 2021;21:168.
    PubMed     Abstract available

  286. JIANG H, Li H
    Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:149.
    PubMed     Abstract available

  287. TAN W, Liu M, Wang L, Guo Y, et al
    Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer.
    BMC Cancer. 2021;21:126.
    PubMed     Abstract available

  288. JIAO D, Zhang J, Zhu J, Guo X, et al
    Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
    BMC Cancer. 2021;21:138.
    PubMed     Abstract available

  289. LIU M, Liu S, Yang L, Wang S, et al
    Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:118.
    PubMed     Abstract available

  290. THUREAU S, Marchesi V, Vieillard MH, Perrier L, et al
    Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase II
    BMC Cancer. 2021;21:117.
    PubMed     Abstract available

  291. YANG Q, Zhong X, Zhang W, Luo T, et al
    Cost-effectiveness of different surgical treatment approaches for early breast cancer: a retrospective matched cohort study from China.
    BMC Cancer. 2021;21:107.
    PubMed     Abstract available

  292. KAWAMOTO T, Shikama N, Kurokawa C, Hara N, et al
    A prospective feasibility study of a 1-mm bolus for postmastectomy radiotherapy.
    BMC Cancer. 2021;21:109.
    PubMed     Abstract available

    January 2021
  293. BEACHLER DC, de Luise C, Jamal-Allial A, Yin R, et al
    Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.
    BMC Cancer. 2021;21:97.
    PubMed     Abstract available

  294. WHITEHEAD I, Irwin GW, Bannon F, Coles CE, et al
    The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making.
    BMC Cancer. 2021;21:90.
    PubMed     Abstract available

  295. JUNG SM, Jeon BJ, Woo J, Ryu JM, et al
    Does chemotherapy or radiotherapy affect the postoperative complication in breast cancer patients who underwent immediate breast reconstruction with tissue expander?
    BMC Cancer. 2021;21:88.
    PubMed     Abstract available

  296. HUO X, Li J, Zhao F, Ren D, et al
    The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:78.
    PubMed     Abstract available

  297. EVANGELISTA AF, Oliveira RJ, O Silva VA, D C Vieira RA, et al
    Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    BMC Cancer. 2021;21:76.
    PubMed     Abstract available

  298. BASET Z, Abdul-Ghafar J, Parpio YN, Haidary AM, et al
    Risk factors of breast cancer among patients in a tertiary care hospitals in Afghanistan: a case control study.
    BMC Cancer. 2021;21:71.
    PubMed     Abstract available

  299. GENG SK, Fu SM, Ma SH, Fu YP, et al
    Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    BMC Cancer. 2021;21:68.
    PubMed     Abstract available

  300. OO KK, Kamolhan T, Soni A, Thongchot S, et al
    Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer.
    BMC Cancer. 2021;21:65.
    PubMed     Abstract available

  301. FIROUZABADI D, Dehghanian A, Rezvani A, Mahmoudi L, et al
    Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
    BMC Cancer. 2021;21:47.
    PubMed     Abstract available

  302. NAKATSUKASA K, Niikura N, Kashiwabara K, Amemiya T, et al
    Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
    BMC Cancer. 2021;21:34.
    PubMed     Abstract available

  303. MOSLEMI M, Moradi Y, Dehghanbanadaki H, Afkhami H, et al
    The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:27.
    PubMed     Abstract available

    December 2020
  304. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    BMC Cancer. 2020;20:1215.
    PubMed     Abstract available

  305. DESA DE, Strawderman RL, Wu W, Hill RL, et al
    Intratumoral heterogeneity of second-harmonic generation scattering from tumor collagen and its effects on metastatic risk prediction.
    BMC Cancer. 2020;20:1217.
    PubMed     Abstract available

  306. KIM JY, Jung EJ, Kim JM, Lee HS, et al
    Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis.
    BMC Cancer. 2020;20:1206.
    PubMed     Abstract available

  307. BAO H, Wang L, Brown M, Zhang M, et al
    A nationally quasi-experimental study to assess the impact of partial organized breast and cervical cancer screening programme on participation and inequalities.
    BMC Cancer. 2020;20:1191.
    PubMed     Abstract available

  308. KROZ M, Reif M, Glinz A, Berger B, et al
    Correction to: Impact of a combined multimodal-aerobic and multimodal intervention compared to standard aerobic treatment in breast cancer survivors with chronic cancer-related fatigue - results of a three-armed pragmatic trial in a comprehensive coho
    BMC Cancer. 2020;20:1174.
    PubMed     Abstract available

  309. TORRES-ROMAN JS, Martinez-Herrera JF, Carioli G, Ybaseta-Medina J, et al
    Breast cancer mortality trends in Peruvian women.
    BMC Cancer. 2020;20:1173.
    PubMed     Abstract available

    November 2020
  310. BISWAS A, Mukherjee G, Kondaiah P, Desai KV, et al
    Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer.
    BMC Cancer. 2020;20:1159.
    PubMed     Abstract available

  311. SUN GY, Wen G, Zhang YJ, Tang Y, et al
    Radiotherapy plays an important role in improving the survival outcome in patients with T1-2N1M0 breast cancer - a joint analysis of 4262 real world cases from two institutions.
    BMC Cancer. 2020;20:1155.
    PubMed     Abstract available

  312. ZHANG Z, Zheng Q, Liu Y, Sun L, et al
    Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells.
    BMC Cancer. 2020;20:1158.
    PubMed     Abstract available

  313. GAO ZH, Li CX, Liu M, Jiang JY, et al
    Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    BMC Cancer. 2020;20:1150.
    PubMed     Abstract available

  314. ZHANG L, Tang R, Deng JP, Zhang WW, et al
    The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer.
    BMC Cancer. 2020;20:1146.
    PubMed     Abstract available

  315. WANG J, Tang Y, Jing H, Sun G, et al
    Risk stratification for prediction of locoregional recurrence in patients with pathologic T1-2N0 breast cancer after mastectomy.
    BMC Cancer. 2020;20:1132.
    PubMed     Abstract available

  316. BERGER E, Maitre N, Romana Mancini F, Baglietto L, et al
    The impact of lifecourse socio-economic position and individual social mobility on breast cancer risk.
    BMC Cancer. 2020;20:1138.
    PubMed     Abstract available

  317. SHIRMOHAMMADI E, Ebrahimi SS, Farshchi A, Salimi M, et al
    Correction to: The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages.
    BMC Cancer. 2020;20:1126.
    PubMed     Abstract available

  318. KAPLAN HG, Malmgren JA, Atwood MK
    Breast cancer distant recurrence lead time interval by detection method in an institutional cohort.
    BMC Cancer. 2020;20:1124.
    PubMed     Abstract available

  319. MARINELLI O, Romagnoli E, Maggi F, Nabissi M, et al
    Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER(+)HER2(-)Rb wild-type and knock-down in breast cancer cell lines.
    BMC Cancer. 2020;20:1119.
    PubMed     Abstract available

  320. PU S, Wang K, Liu Y, Liao X, et al
    Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT).
    BMC Cancer. 2020;20:1120.
    PubMed     Abstract available

  321. REZNICZEK GA, Giger-Pabst U, Thaher O, Tempfer CB, et al
    Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer.
    BMC Cancer. 2020;20:1122.
    PubMed     Abstract available

  322. LEE IH, Lee SJ, Lee J, Jung JH, et al
    Utility of (18)F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.
    BMC Cancer. 2020;20:1106.
    PubMed     Abstract available

  323. LI X, Zhang X, Liu J, Shen Y, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    BMC Cancer. 2020;20:1102.
    PubMed     Abstract available

  324. FENG R, Jing J, Zhang X, Li M, et al
    Adherence to post-surgery follow-up assessment and its association with sociodemographic and disease characteristics in patients with breast cancer in Central China.
    BMC Cancer. 2020;20:1098.
    PubMed     Abstract available

  325. PITTALIS C, Panteli E, Schouten E, Magongwa I, et al
    Breast and cervical cancer screening services in Malawi: a systematic review.
    BMC Cancer. 2020;20:1101.
    PubMed     Abstract available

  326. HERNANDEZ VARGAS JA, Ramirez Barbosa PX, Gil Quijano AM, Valbuena AM, et al
    Patterns of breast, prostate and cervical cancer incidence and mortality in Colombia: an administrative registry data analysis.
    BMC Cancer. 2020;20:1097.
    PubMed     Abstract available

  327. NG CWQ, Lim JNW, Liu J, Hartman M, et al
    Presentation of breast cancer, help seeking behaviour and experience of patients in their cancer journey in Singapore: a qualitative study.
    BMC Cancer. 2020;20:1080.
    PubMed     Abstract available

  328. MALIK R, Vera N, Dayal C, Choudhari A, et al
    Factors associated with breast cancer awareness and breast self-examination in Fiji and Kashmir India - a cross-sectional study.
    BMC Cancer. 2020;20:1078.
    PubMed     Abstract available

  329. RING A, Kaur P, Lang JE
    EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    BMC Cancer. 2020;20:1076.
    PubMed     Abstract available

  330. TRIVINO JC, Ceba A, Rubio-Solsona E, Serra D, et al
    Combination of phenotype and polygenic risk score in breast cancer risk evaluation in the Spanish population: a case -control study.
    BMC Cancer. 2020;20:1079.
    PubMed     Abstract available

  331. MUNOZ-ALCARAZ MN, Perula-de-Torres LA, Serrano-Merino J, Jimenez-Vilchez AJ, et al
    Efficacy and efficiency of a new therapeutic approach based on activity-oriented proprioceptive antiedema therapy (TAPA) for edema reduction and improved occupational performance in the rehabilitation of breast cancer-related arm lymphedema in women:
    BMC Cancer. 2020;20:1074.
    PubMed     Abstract available

  332. NI M, Zhou X, Liu J, Yu H, et al
    Prediction of the clinicopathological subtypes of breast cancer using a fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI.
    BMC Cancer. 2020;20:1073.
    PubMed     Abstract available

  333. YANAI K, Fujii T, Horiguchi J, Nakazawa Y, et al
    Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer.
    BMC Cancer. 2020;20:1068.
    PubMed     Abstract available

  334. TENTLER JJ, Lang J, Capasso A, Kim DJ, et al
    RX-5902, a novel beta-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    BMC Cancer. 2020;20:1063.
    PubMed     Abstract available

  335. LIM GB, Kim YA, Seo JH, Lee HJ, et al
    Prediction of prognostic signatures in triple-negative breast cancer based on the differential expression analysis via NanoString nCounter immune panel.
    BMC Cancer. 2020;20:1052.
    PubMed     Abstract available

  336. KWONG A, Shin VY, Ho CYS, Au CH, et al
    Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.
    BMC Cancer. 2020;20:1053.
    PubMed     Abstract available

  337. XU H, Liu Z, Shi H, Wang C, et al
    Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:1051.
    PubMed     Abstract available

    October 2020
  338. ENNOUR-IDRISSI K, Dragic D, Durocher F, Diorio C, et al
    Epigenome-wide DNA methylation and risk of breast cancer: a systematic review.
    BMC Cancer. 2020;20:1048.
    PubMed     Abstract available

  339. SHAMSHIRIAN A, Aref AR, Yip GW, Ebrahimi Warkiani M, et al
    Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:1049.
    PubMed     Abstract available

  340. WEI C, Li X
    Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
    BMC Cancer. 2020;20:1042.
    PubMed     Abstract available

  341. LEI YY, Ho SC, Kwok C, Cheng A, et al
    Longitudinal changes in sports activity from pre-diagnosis to first five years post-diagnosis: a prospective Chinese breast cancer cohort study.
    BMC Cancer. 2020;20:1013.
    PubMed     Abstract available

  342. AGBEKO AE, Arthur J, Bayuo J, Kaburi BB, et al
    Seeking healthcare at their 'right' time; the iterative decision process for women with breast cancer.
    BMC Cancer. 2020;20:1011.
    PubMed     Abstract available

  343. MA T, Liu H, Liu Y, Liu T, et al
    USP6NL mediated by LINC00689/miR-142-3p promotes the development of triple-negative breast cancer.
    BMC Cancer. 2020;20:998.
    PubMed     Abstract available

  344. LI X, Zhou C, Wu Y, Chen X, et al
    Relationship between formulaic breast volume and risk of breast cancer based on linear measurements.
    BMC Cancer. 2020;20:989.
    PubMed     Abstract available

  345. ZHAO W, Wu L, Zhao A, Zhang M, et al
    A nomogram for predicting survival in patients with de novo metastatic breast cancer: a population-based study.
    BMC Cancer. 2020;20:982.
    PubMed     Abstract available

  346. RAINEY L, van der Waal D, Broeders MJM
    Dutch women's intended participation in a risk-based breast cancer screening and prevention programme: a survey study identifying preferences, facilitators and barriers.
    BMC Cancer. 2020;20:965.
    PubMed     Abstract available

  347. XIA L, Li F, Qiu J, Feng Z, et al
    Oncogenic miR-20b-5p contributes to malignant behaviors of breast cancer stem cells by bidirectionally regulating CCND1 and E2F1.
    BMC Cancer. 2020;20:949.
    PubMed     Abstract available

  348. CULBERTSON MG, Bennett K, Kelly CM, Sharp L, et al
    The psychosocial determinants of quality of life in breast cancer survivors: a scoping review.
    BMC Cancer. 2020;20:948.
    PubMed     Abstract available

  349. NIU S, Huang J, Li J, Liu X, et al
    Application of ultrasound artificial intelligence in the differential diagnosis between benign and malignant breast lesions of BI-RADS 4A.
    BMC Cancer. 2020;20:959.
    PubMed     Abstract available

  350. AKAHANE T, Kanomata N, Harada O, Yamashita T, et al
    Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
    BMC Cancer. 2020;20:944.
    PubMed     Abstract available

    September 2020
  351. LEE J, Jung JH, Kim WW, Park CS, et al
    Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma.
    BMC Cancer. 2020;20:934.
    PubMed     Abstract available

  352. INARI H, Teruya N, Kishi M, Horii R, et al
    Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis.
    BMC Cancer. 2020;20:932.
    PubMed     Abstract available

  353. FUJITA M, Imadome K, Somasundaram V, Kawanishi M, et al
    Metabolic characterization of aggressive breast cancer cells exhibiting invasive phenotype: impact of non-cytotoxic doses of 2-DG on diminishing invasiveness.
    BMC Cancer. 2020;20:929.
    PubMed     Abstract available

  354. YANG H, Xu Y, Zhao Y, Yin J, et al
    The role of tissue elasticity in the differential diagnosis of benign and malignant breast lesions using shear wave elastography.
    BMC Cancer. 2020;20:930.
    PubMed     Abstract available

    August 2020
  355. HICKS BM, Busby J, Mills K, O'Neil FA, et al
    Post-diagnostic antipsychotic use and cancer mortality: a population based cohort study.
    BMC Cancer. 2020;20:804.
    PubMed     Abstract available

  356. ALEXEEV SM, Khorinko AV, Mukhametshina GZ, Shelepen KG, et al
    Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.
    BMC Cancer. 2020;20:783.
    PubMed     Abstract available

  357. ZHONG L, Xie L, Yang Z, Li L, et al
    Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
    BMC Cancer. 2020;20:766.
    PubMed     Abstract available

  358. EL ANSARI FZ, Jouali F, Marchoudi N, Bennani MM, et al
    Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    BMC Cancer. 2020;20:747.
    PubMed     Abstract available

  359. GWYNNE WD, Shakeel MS, Girgis-Gabardo A, Kim KH, et al
    Antagonists of the serotonin receptor 5A target human breast tumor initiating cells.
    BMC Cancer. 2020;20:724.
    PubMed     Abstract available

    July 2020
  360. PENG C, DuPre N, VoPham T, Heng YJ, et al
    Low dose environmental radon exposure and breast tumor gene expression.
    BMC Cancer. 2020;20:695.
    PubMed     Abstract available

  361. ABSIL L, Journe F, Larsimont D, Body JJ, et al
    Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells.
    BMC Cancer. 2020;20:640.
    PubMed     Abstract available

  362. WRIGHT CM, Halkett G, Carey Smith R, Moorin R, et al
    Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data.
    BMC Cancer. 2020;20:625.
    PubMed     Abstract available

  363. RUHNAU J, Parczyk J, Danker K, Eickholt B, et al
    Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism.
    BMC Cancer. 2020;20:617.
    PubMed     Abstract available

    June 2020
  364. TORGBENU E, Luckett T, Buhagiar MA, Chang S, et al
    Prevalence and incidence of cancer related lymphedema in low and middle-income countries: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:604.
    PubMed     Abstract available

  365. KNAUL FM, Doubova SV, Gonzalez Robledo MC, Durstine A, et al
    Self-identity, lived experiences, and challenges of breast, cervical, and prostate cancer survivorship in Mexico: a qualitative study.
    BMC Cancer. 2020;20:577.
    PubMed     Abstract available

  366. PU Q, Lv YR, Dong K, Geng WW, et al
    Tumor suppressor OTUD3 induces growth inhibition and apoptosis by directly deubiquitinating and stabilizing p53 in invasive breast carcinoma cells.
    BMC Cancer. 2020;20:583.
    PubMed     Abstract available

  367. FRENCH DP, Astley S, Brentnall AR, Cuzick J, et al
    What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420).
    BMC Cancer. 2020;20:570.
    PubMed     Abstract available

  368. BOLDES T, Merenbakh-Lamin K, Journo S, Shachar E, et al
    R269C variant of ESR1: high prevalence and differential function in a subset of pancreatic cancers.
    BMC Cancer. 2020;20:531.
    PubMed     Abstract available

  369. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
    BMC Cancer. 2020;20:513.
    PubMed     Abstract available

  370. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
    Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    BMC Cancer. 2020;20:501.
    PubMed     Abstract available

    May 2020
  371. NILSSEN Y, Brustugun OT, Eriksen MT, Haug ES, et al
    Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
    BMC Cancer. 2020;20:488.
    PubMed     Abstract available

  372. LIU H, Zhan H, Sun D
    Comparison of (99m)Tc-MIBI scintigraphy, ultrasound, and mammography for the diagnosis of BI-RADS 4 category lesions.
    BMC Cancer. 2020;20:463.
    PubMed     Abstract available

  373. WOOF VG, Ruane H, French DP, Ulph F, et al
    The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women.
    BMC Cancer. 2020;20:452.
    PubMed     Abstract available

  374. LIN J, Lin KJ, Wang YF, Huang LH, et al
    Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy.
    BMC Cancer. 2020;20:451.
    PubMed     Abstract available

  375. FAHLBUSCH SS, Keil S, Epplen JT, Zanker KS, et al
    Comparison of hybrid clones derived from human breast epithelial cells and three different cancer cell lines regarding in vitro cancer stem/ initiating cell properties.
    BMC Cancer. 2020;20:446.
    PubMed     Abstract available

  376. EGELAND NG, Jonsdottir K, Aure MR, Sahlberg K, et al
    MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers.
    BMC Cancer. 2020;20:377.
    PubMed     Abstract available

  377. PARK JH, Lee DH, Kim SI, Kim NK, et al
    Moderate to vigorous physical activity participation associated with better quality of life among breast and colorectal cancer survivors in Korea.
    BMC Cancer. 2020;20:365.
    PubMed     Abstract available

    April 2020
  378. NYHOF BB, Wright FC, Look Hong NJ, Groot G, et al
    Identifying opportunities to support patient-centred care for ductal carcinoma in situ: qualitative interviews with clinicians.
    BMC Cancer. 2020;20:364.
    PubMed     Abstract available

  379. THERKILDSEN C, Rasmussen M, Smith-Hansen L, Kallemose T, et al
    Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort.
    BMC Cancer. 2020;20:345.
    PubMed     Abstract available

  380. TANABE Y, Shiraishi S, Hashimoto K, Ikeda K, et al
    Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
    BMC Cancer. 2020;20:325.
    PubMed     Abstract available

    March 2020
  381. WATANABE K, Katayama K, Yoshioka T, Narimatsu H, et al
    Impact of individual background on the unmet needs of cancer survivors and caregivers - a mixed-methods analysis.
    BMC Cancer. 2020;20:263.
    PubMed     Abstract available

  382. MOSS C, Haire A, Cahill F, Enting D, et al
    Guy's cancer cohort - real world evidence for cancer pathways.
    BMC Cancer. 2020;20:187.
    PubMed     Abstract available

  383. PRZYBYTKOWSKI E, Davis T, Hosny A, Eismann J, et al
    An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    BMC Cancer. 2020;20:197.
    PubMed     Abstract available

    February 2020
  384. PESSOA-PEREIRA D, Evangelista AF, Causin RL, da Costa Vieira RA, et al
    miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
    BMC Cancer. 2020;20:143.
    PubMed     Abstract available

  385. HU G, Hu G, Zhang C, Lin X, et al
    Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    BMC Cancer. 2020;20:136.
    PubMed     Abstract available

  386. DETTOGNI RS, Stur E, Laus AC, da Costa Vieira RA, et al
    Potential biomarkers of ductal carcinoma in situ progression.
    BMC Cancer. 2020;20:119.
    PubMed     Abstract available

    January 2020
  387. MANOHARAN V, Karunanayake EH, Tennekoon KH, De Silva S, et al
    Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    BMC Cancer. 2020;20:72.
    PubMed     Abstract available

  388. HA JH, Hong KY, Lee HB, Moon HG, et al
    Oncologic outcomes after immediate breast reconstruction following mastectomy: comparison of implant and flap using propensity score matching.
    BMC Cancer. 2020;20:78.
    PubMed     Abstract available

  389. NAWAS AF, Kanchwala M, Thomas-Jardin SE, Dahl H, et al
    IL-1-conferred gene expression pattern in ERalpha(+) BCa and AR(+) PCa cells is intrinsic to ERalpha(-) BCa and AR(-) PCa cells and promotes cell survival.
    BMC Cancer. 2020;20:46.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.